drugset / Trial / NCT00944541
Evaluation of Maraviroc Intensification in HIV Infected Patients With Insufficient Immune Restoration
Phase 2
Completed
60 enrolled
French National Agency for Research on AIDS and Viral Hepatitis
Pfizer · collab
Non-randomizedCrossoverOpen-labelTreatment
Summary
This pilot study aims to evaluate Maraviroc intensification strategy during 24 weeks in HIV infected patients under efficient (CV\< 50 cp/mL), controlled antiretroviral therapy (≥ 6 months) and uncompleted immune restoration (CD4\<350 cells/mL and CD4 earning \<100 cells/mL during last 24 months). The study will include 60 patients whose follow up is carried out for 48 weeks. recruitment period will be maintained for 12 months.
Timeline
- Start
- 2009-09
- Primary completion
- 2010-08
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Maraviroc | Other / unclassified | 150 mg | — |
| Subject | Maraviroc | Other / unclassified | 300 mg | — |
| Subject | Maraviroc | Other / unclassified | 600 mg | — |